FederalDue in 18 days · Oct 5, 2026
Fort Worth District
1) Note: A full study proposal and proposed budget are NOT requested at this time.
2) Project Title: Wading Bird Response to Ecosystem Restoration in Southwest Florida.
3) Brief Description of Anticipated Work: See attached SOO for this information.
4) Period of Performance: Base period: 12 months from date of award. Follow-on (FO) periods: (4) Four 12-month FO periods. Optional Task 5: Up to 24 months from date of award and Optional Task 6: 12 months from date of award.
5) Please send responses or direct questions to:
Nicholas Aprea
Grants Specialist
USACE, Fort Worth District
Email: nicholas.a.aprea@usace.army.mil
Emily Woodruff
Project Manager
USACE, Fort Worth District
Email: emily.t.woodruff@usace.army.mil
6) Timeline for Review of Statements of Interest: 30 calendar days from date posted.
$250,000 – $1,960,000Official notice ↗ FederalDue in 18 days · Oct 5, 2026
Fort Worth District
1) Note: A full study proposal and proposed budget are NOT requested at this time.
2) Project Title: Aquatic Fauna and Primary Production in the Florida Everglades
3) Brief Description of Anticipated Work: See Attached SOO.
4) Period of Performance: Base period: 12 months from date of award. Follow-on (FO) periods: (4) four 12-month FO periods
5) Please send responses or direct questions to:
Nicholas Aprea
Grants Specialist
USACE, Fort Worth District
Email: nicholas.a.aprea@usace.army.mil
Kathy Mitchell
Project Manager
USACE, Fort Worth District
Email: kathy.s.mitchell@usace.army.mil
6) Timeline for Review of Statements of Interest: 30 calendar days from date posted.
$996,800 – $4,984,000Official notice ↗ FederalDue in 18 days · Oct 5, 2026
Fort Worth District
1) Note: A full study proposal and proposed budget are NOT requested at this time.
2) Project Title: American Alligators as Ecological Indicators of Everglades Restoration.
3) Brief Description of Anticipated Work: See Attached SOO for more information.
4) Period of Performance: Base period: 12 months from date of award. Follow-on (FO) periods: 4 12-month FO periods.
5) Please send responses or direct questions to:
Nicholas Aprea
Grants Specialist
USACE, Fort Worth District
Email: nicholas.a.aprea@usace.army.mil
Kathy Mitchell
Project Manager
USACE, Fort Worth District
Email: kathy.s.mitchell@usace.army.mil
6) Timeline for Review of Statements of Interest: 30 calendar days from date posted.
$391,856 – $1,546,800Official notice ↗ FederalDue in 20 days · Oct 7, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas.
· This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials.
· The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Amount not specifiedOfficial notice ↗ FederalDue in 20 days · Oct 7, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism supports innovative ideas with the potential to yield impactful data and new avenues of investigation. All applications must address at least one of the FY26 PCARP Focus Areas.
Distinctive Features:
This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.
Partnering Principal Investigator (PI) Option for Early-Career Investigator: This funding mechanism offers a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research. For this option, only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Amount not specifiedOfficial notice ↗ FederalDue in 20 days · Oct 7, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application.
Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.
Amount not specifiedOfficial notice ↗ FederalDue in 22 days · Oct 9, 2026
National Institutes of Health
The overarching goal of this notice of funding opportunity (NOFO) and its companion opportunities is to establish the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program to support development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools. PRIMED-AI CDS tools are based on the integration of clinical imaging with other types of multimodal health data to enhance care for patients with a wide range of health conditions. The PRIMED-AI Program seeks to catalyze the adoption of AI-based CDS tools into clinical workflows to enable novel personalized medicine strategies that address significant health challenges. The purpose of this NOFO is to solicit applications for the design, development, and preliminary validation of robust frameworks for the application of multimodal-artificial intelligence (AI) models for clinical use. Frameworks developed through these awards would populate a "playbook", defined as a collection of actionable guidelines, standardized protocols, and/or standard operating procedures (SOPs) for reliable and effective development and deployment of multimodal AI tools. It is expected that the frameworks delineated in this playbook will directly address PRIMED-AI objectives and needs, while also remaining flexible enough to enable sufficient extensibility and interoperability for use across a broad spectrum of multimodal biomedical AI applications, both internal and external to the PRIMED-AI Program.
FederalDue in 22 days · Oct 9, 2026
Dept of the Army -- Materiel Command
Under the authority of 10 U.S.C. § 4144, in alignment with Section 223 of the FY 2026 National Defense Authorization Act (NDAA), funding in the FY 2026 defense appropriations, and, Presidential Executive Order 14332, Improving Oversight of Federal Grantmaking, the DoW announces this funding opportunity for the acquisition of equipment/instrumentation at Historically Black Colleges and Universities (HBCUs) and Tribal Colleges and Universities (TCUs).
The program is executed under policy and guidance of the Office of the Under Secretary of War for Research and Engineering (OUSW(R&E)) and is administered by ARL, ONR, and AFOSR, hereafter called “the Agencies.”
This Notification of Funding Opportunity (NOFO) aims to (a) enhance research and education programs and capabilities in scientific and engineering disciplines critical to the national security functions of DoW; (b) enhance the capacity of HBCUs and TCUs to participate in DoW research programs and activities; and (c) increase the number of graduates in the fields of science, technology, engineering, and mathematics (STEM). The DoW is announcing this research solicitation based on 10 U.S.C. § 4144 and Section 223 of the FY 2026 NDAA (https://www.congress.gov/119/bills/s1071/BILLS-119s1071enr.pdf), which directs for fiscal year 2026 and each fiscal year thereafter, the Secretary of Defense to ensure that funding solicitations through the DoW HBCU/MI Program Element include separate funding solicitations each focused toward: (1) Historically Black Colleges and Universities and Tribal Colleges; and (2) Minority-Serving Institutions that are not HBCUs or TCUs. Also informing this solicitation is Section 262 of the NDAA for FY 2020 (https://www.congress.gov/116/plaws/publ92/PLAW-116publ92.pdf), section 220 of the NDAA for FY 2022 (https://www.congress.gov/117/plaws/publ81/PLAW-117publ81.pdf), and the publication of the National Academies of Sciences, Engineering, and Medicine titled “Defense Research Capacity at Historically Black Colleges and Universities and Other Minority Institutions: Transitioning from Good Intentions to Measurable Outcomes” dated April 28, 2022 (https://www.nationalacademies.org/publications/26399).
The DoW is soliciting applications (also referred to as “proposals”) for the acquisition of equipment/instrumentation under the Fiscal Year 2027 Research and Education Program for HBCU/MI. The Research and Education Program is designed to enhance the research capabilities of HBCUs and MIs and to strengthen their STEM education programs. The purpose of the funding under this NOFO is to (1) support the acquisition of equipment/instrumentation to augment existing capabilities or to develop new capabilities in research areas of interest to DoW, and (2) attract students to pursue studies leading to STEM careers. Although funding provided under this NOFO cannot be used for student support, in order to further DoW’s objective of attracting students to pursue studies leading to STEM careers, applicants must address the impact of the requested equipment/instrumentation on student participation in research.
The proposals must align with the research areas of interest to the DoW (which includes the USW(R&E) and the Agencies) and enhance the education of students in areas of STEM that align with the DoW research interests.
$200,000 – $1,500,000Official notice ↗ FederalDue in 22 days · Oct 9, 2026
National Institutes of Health
This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).
Amount not specifiedOfficial notice ↗ FederalDue in 22 days · Oct 9, 2026
National Institutes of Health
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO (RFA-DK-27-136).
FederalDue in 24 days · Oct 11, 2026
National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
Amount not specifiedOfficial notice ↗ FederalDue in 25 days · Oct 12, 2026
Fort Worth District
Note: A full study proposal and proposed budget are NOT requested at this time.
Project Title: Aquatic Fauna Response to Ecosystem Restoration in Southwest Florida
Brief Description of Anticipated Work: See attached SOO for this information.
Period of Performance: The base period of the agreement will extend 12 months from date of award. There may be up to four 12-month Follow-On Periods based on availability of funding.
Please send responses or direct questions to:
Maria Lopez
Grants Specialist
USACE, Fort Worth District
Email: Maria.E.Lopez@usace.army.mil
AND
Emily Woodruff
Project Manager
USACE, Fort Worth District
Email: Emily.T.Woodruff@usace.army.mil
Timeline for Review of Statements of Interest: RSOIs are required to be posted on www.Grants.gov for 30 days prior to the Government making a decision and requesting full proposals.
$300,000 – $1,925,000Official notice ↗ FederalDue in 27 days · Oct 14, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas.
Distinctive Features:
· *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact.
· This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1.
Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).
· After submitting the required pre-application, investigators must receive an invitation to submit a full application.
Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project.
· Clinical trials are allowed.
Amount not specifiedOfficial notice ↗ FederalDue in 27 days · Oct 14, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care. Team science is a synergistic effort that harnesses techniques, approaches and perspectives from multiple disciplines and/or therapeutic areas to address complex, multi-dimensional problems that will impact patient outcomes.
Distinctive Features:
· This funding mechanism requires multiple Principal Investigators (PIs). At least two and up to three PIs should partner to jointly design and execute a single research project; multi-institutional partnerships are encouraged. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).
· Consumer Collaboration Option: Investigators are encouraged, but not required, to form collaborative relationships with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended community(ies).
· After submitting the required pre-application, investigators must receive an invitation to submit a full application.
Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research effort.
Amount not specifiedOfficial notice ↗ FederalDue in 27 days · Oct 14, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life, overall health and/or function are not responsive to this funding opportunity.
Distinctive Features:
· The application must include at least one melanoma consumer collaborator, defined as a melanoma survivor, family member and/or care partner who can provide lived experience expertise to the research project team, or a melanoma-community supporting organization to support the planning, execution, and implementation of the proposed research.
· Clinical trials are allowed.
Amount not specifiedOfficial notice ↗ FederalDue in 27 days · Oct 14, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Idea Award supports innovative, exploratory, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project. By the end of the Idea Award funding period, the anticipated outcomes of successful efforts should establish proof of principle and obtain preliminary data to secure follow-on funding.
Distinctive Features:
• Preliminary data are discouraged.
• After submitting the required pre-application, investigators must receive an invitation to submit a full application.
Amount not specifiedOfficial notice ↗ FederalDue in 28 days · Oct 15, 2026
National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to foster research that will inform and support the optimization, delivery, sustainability, and effectiveness of empirically-supported practices for addressing the mental health needs of older adults with serious mental illness (SMI). To this end, NIMH seeks applications that propose work that is focused on practice-relevant questions and conducted within and/or across settings where older adults with SMI are likely to be identified as needing care (e.g., primary care and geriatric specialty clinics, assisted living and long-term care facilities, and community centers). Applications may propose research related to adapting, optimizing, and implementing efficacious treatment and services interventions and strategies to improve clinical and functional outcomes among aging populations; examining mutable factors that impact fair and impartial mental health care access, utilization, quality, and outcomes and may serve as targets for intervention development for older adults with SMI; and developing and testing innovative treatment and service interventions that address barriers to accessing quality mental health care. Projects may also focus on systems-level factors and approaches for addressing SMI and improving access to evidence-based interventions in later life, such as evaluation of health system policies and practices, interventions that facilitate care transitions and continuity across settings, and strategies to improve care linkages and coordination across systems.
Amount not specifiedOfficial notice ↗ FederalDue in 28 days · Oct 15, 2026
National Institutes of Health
The goal of this NOFO is to support doctoral candidates studying high-priority areas of child health for the completion of their doctoral dissertation research project. This NOFO seeks to advance research in child health by stimulating the use of Environmental Influences on Child Health (ECHO) Cohort data by doctoral students in relevant scientific areas. This RFA will provide students working on dissertations the opportunity to access the ECHO data within the NICHD Data and Specimen Hub (DASH) repository. ECHO"s DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO"s five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health. This award will facilitate the entry of promising new investigators into the field of early environmental exposures and child health research, enhancing the pool of highly talented researchers.
Amount not specifiedOfficial notice ↗ FederalDue in 28 days · Oct 15, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.
Distinctive Features: Funding from this award mechanism must support a clinical trial.
· Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.
· Preliminary data are required.
· The inclusion of community-based participatory research (CBPR) approaches is required.
· The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.
○ Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.
○ Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.
· Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.
Amount not specifiedOfficial notice ↗ FederalDue in 28 days · Oct 15, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research. Submissions focusing on minor modifications to existing standards without the intent or potential to significantly improve clinical care or patient outcomes do not meet the intent of the mechanism.
Distinctive Features: Basic research and clinical trials are prohibited. Preliminary data are required.
· For animal research, applications must describe the choice of model and its relevance to the human clinical condition.
· For research prospectively enrolling human subjects, the inclusion of community-based participatory research (CBPR) approaches is required.
· The Translational Research Award offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.
○ Research Level 1: Supports the refinement of mature ideas and concepts into tangible and knowledge products positioned for further evaluation.
○ Research Level 2: Supports the rigorous evaluation of tangible and knowledge products in preparation for first-in-human studies or clinical trials.
· Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.
Amount not specifiedOfficial notice ↗ FederalDue in 28 days · Oct 15, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches.
Distinctive Features:
· The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights.
· Applications must include clinical research or clinical trials. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed.
· Preliminary data are required.
· Basic, preclinical and animal research are prohibited.
· For research prospectively enrolling human subjects, inclusion of community-based participatory research (CBPR) approaches is required.
· Early-Career Investigator Partnering Option: This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.
Amount not specifiedOfficial notice ↗ CADue in 29 days · Oct 16, 2026
Governor's Office of Emergency Services
The purpose of the Intimate Partner Violence Prevention (FD) Program is to prevent intimate partner violence, including teen dating violence, and sexual assault.
To create or expand Intimate Partner Violence, Sexual Assault, and Teen Dating Violence prevention programs.
FederalDue in 29 days · Oct 16, 2026
Centers for Disease Control-GHC
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $500,000 for Year 1, subject to the availability of funds.This NOFO provides operational support through financial and technical resources to the Ghana Health Service (GHS)/Ministry of Health (MoH). The goal is to help them coordinate and improve laboratory capacity so they can deliver high-quality, efficient services for HIV, TB, and other priority health areas. This NOFO will advance HIV testing, treatment, retention, and viral suppression in Ghana by:Equipping laboratories with appropriate diagnostic technologies.Building staff skills to manage quality laboratory services.Strengthening the capacity of the Government of Ghana (GoG) MoH to take full responsibility for managing laboratory services, diagnostic networks, and systems for HIV, TB, and other priority infectious diseases.
Amount not specifiedOfficial notice ↗ FederalDue in 29 days · Oct 16, 2026
Bureau of International Narcotics-Law Enforcement
The Bureau of International Narcotics and Law Enforcement Affairs of the U.S. Department of State announces an open competition for organizations to submit applications to carry out a logistics and travel support project that strengthens public security, justice, and combats illicit drug trafficking and transnational organized crime. Through this cooperative agreement, the grantee will provide logistical, operational, and technical support to the Government of Honduras (GOH) to enhance its ability to prevent, investigate, and prosecute crimes, especially those linked to narcotics trafficking, corruption, and transnational organized crime.
The project’s goal is to improve the operational readiness, professionalism, and coordination of Honduran law enforcement and justice sector institutions. Activities will include managing and supporting training and professional development events; coordinating travel and logistics for operations; conducting procurement of supplies, services, and equipment required for training delivery and operational support; ensuring cost-effectiveness, transparency, and compliance with applicable U.S. Government acquisition regulations; providing limited equipment and maintenance support, and strengthening institutional systems that help government agencies work more efficiently and transparently.
This project benefits Honduran law enforcement personnel, prosecutors, judges, and other justice sector actors who participate in INL-supported initiatives, as well as third-country national (TCN) advisors who provide technical or operational assistance. By improving the government’s ability to respond to crime and uphold justice, the project helps make both Honduras and the United States safer and more secure.
$6,000,000 – $7,000,000Official notice ↗